BRAFV600E promotes glycolysis in melanoma cells via regulation of GLUT1, GLUT3, and HK2. BRAFV600E promotes glycolysis in melanoma cells via regulation.

Slides:

Advertisements

Similar presentations

(Journal of Biomedical and Clinical Sciences)

Advertisements

MicroRNA-558 regulates the expression of cyclooxygenase-2 and IL-1β-induced catabolic effects in human articular chondrocytes S.J. Park, E.J. Cheon,

Cell Physiol Biochem 2015;36: DOI: /

PFKFB3, a Direct Target of p63, Is Required for Proliferation and Inhibits Differentiation in Epidermal Keratinocytes Robert B. Hamanaka, Gökhan M. Mutlu

MAPK pathway inhibitors.

Cdc42 Inhibits ERK-Mediated Collagenase-1 (MMP-1) Expression in Collagen-Activated Human Keratinocytes Maryam G. Rohani, Brian K. Pilcher, Peter Chen,

Julie M. Caldwell, PhD, Carine Blanchard, PhD, Margaret H

Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells by Sergey Krysov, Samantha Dias, Alex Paterson, C.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Volume 21, Issue 11, Pages (December 2017)

CHK1 downregulation upon ERG overexpression.

SOX4 Promotes Proliferative Signals by Regulating Glycolysis through AKT Activation in Melanoma Cells Wei Dai, Xinyuan Xu, Shuli Li, Jingjing Ma, Qiong.

Znf217 overexpression promotes increased cell motility and aberrant epithelial marker expression. Znf217 overexpression promotes increased cell motility.

Yao Zhan, Michael S. Dahabieh, Arjuna Rajakumar, Monica C

Laura S. Bisogno, Matthew B. Friedersdorf, Jack D. Keene

Fig. 1 BX795 suppresses HSV-1 infection.

Volume 23, Issue 3, Pages (March 2013)

Fold Change of hsa-miR-3687 (T/N)(log2)

Integrin α4β1 and TLR4 Cooperate to Induce Fibrotic Gene Expression in Response to Fibronectin’s EDA Domain Rhiannon M. Kelsh-Lasher, Anthony Ambesi,

Kellie J. White, Vincent J. Maffei, Marvin Newton-West, Robert A

Carrie Hayes Sutter, Kristin M

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Fig. 2 In vitro and preclinical study with 18F-MPG.

Junaid Afzal et al. BTS 2017;2:

Volume 20, Issue 2, Pages (February 2012)

Effectively regenerating livers transiently accumulate proliferative IGF2BP3-positive cells. Effectively regenerating livers transiently accumulate proliferative.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway

The up-regulation of Galnt3 by Pi requires activation of the ERK pathway and induction of Egr1 and Etv5. The up-regulation of Galnt3 by Pi requires activation.

Effect of insulin on hepcidin expression in HepG2 cells.

Rosiglitazone induces Pdk4 expression in rat and human adipose tissue ex vivo and in 3T3–F442A adipocytes. Rosiglitazone induces Pdk4 expression in rat.

Correlation between CCL26 production by human bronchial epithelial cells and airway eosinophils: Involvement in patients with severe eosinophilic asthma

Fig. 6 Functional characterization of RdRp activity of the recMeV mutants with modified N proteins. Functional characterization of RdRp activity of the.

CPPED1 (A) and PPARγ2 (B) mRNA expressions in cultured SGBS cells during adipocyte differentiation. CPPED1 (A) and PPARγ2 (B) mRNA expressions in cultured.

Aβ-mediated Ras-MAPK signaling and Cyclin D1 expression in B103 cells are dependent on APP expression and can be reversed with MEK or Ras inhibition. Aβ-mediated.

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state Immunohistochemical analysis.

Fig. 4 Loss of Zic5 derepresses GLUT1/SLC2A1 gene expression.

Peripheral surgery regulates expression of astrocytic markers.

Aberrant regulation of HDAC2 and its association with malignant proliferation of human gastric cancer. Aberrant regulation of HDAC2 and its association.

Figure 1. Chloride channel-3 (CIC-3) expression in breast tumor tissues. (A) Chloride channels (ClC-1–7, CFTR) are expressed in human breast cancer tissues.

Induction of CDCP1 is regulated by Ras in NSCLC cells.

Competition between FLYWCH1/β-catenin and TCF4/β-catenin complexes for their interaction to Tcf-DNA-binding sites. Competition between FLYWCH1/β-catenin.

Changes of gene expression induced by 1 mmol/L valproic acid in vitro.

Activation of Wnt signaling pathway in trastuzumab-resistant cell lines. Activation of Wnt signaling pathway in trastuzumab-resistant cell lines. A, bar.

Neurotensin and insulin induce increases in CTGF, CYR61, and CXCL5 gene expression and stimulate cell proliferation and colony via YAP/TAZ in PDAC cells.

FcRγ signaling regulates BTK activation and mediates PDAC growth.

Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

EGFR signaling regulates transcription of PDGFRβ gene.

Fig. 2 In vitro and preclinical study with 18F-MPG.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E. MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E.

Trametinib and combination promote moDC maturation and decrease moDC viability. Trametinib and combination promote moDC maturation and decrease moDC viability.

Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.

NRAS-mediated resistance to vemurafenib (Vem) is associated with restored glycolysis and can be overcome by combination with a glycolysis inhibitor. NRAS-mediated.

SAHA blocks IR-induced increase of RAD51 protein in MM cells.

The effects of AZD1775 and olaparib on DNA damage response signaling.

Functional SLC6A3 in ccRCC cell lines KMRC3 and SNU-349, but not in conventional cell lines. Functional SLC6A3 in ccRCC cell lines KMRC3 and SNU-349, but.

Levels and activity of c-myc are increased in a series of stably transfected DAOY and UW228 medulloblastoma cell lines. Levels and activity of c-myc are.

Inhibition of CD20 mRNA expression by ibrutinib correlates with reduced NF-κB activity. Inhibition of CD20 mRNA expression by ibrutinib correlates with.

TGFβ1/Smad3 signaling suppresses IFNγ production via an E4BP4-dependent mechanism in NK-92 cells. TGFβ1/Smad3 signaling suppresses IFNγ production via.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

PARP1 suppresses the transcription of PD-L1 in cancer cells.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Mutational load and mutations in the interferon signaling pathway among patients with advanced melanoma with or without response to anti–PD-1 blockade.

NUAK1 overexpression correlates with tumor progression, lymph node infiltrates, and reduced overall survival (OS) in human colorectal cancer. NUAK1 overexpression.

IL-17 signaling upregulates ABIN-1 mRNA but downregulates protein.

Trametinib and combination decrease T-lymphocyte proliferation.

Presentation transcript:

BRAFV600E promotes glycolysis in melanoma cells via regulation of GLUT1, GLUT3, and HK2. BRAFV600E promotes glycolysis in melanoma cells via regulation of GLUT1, GLUT3, and HK2. A, [3H]-2DOG uptake in melanoma cells [expressed as percentage change; control vs. 3 μmol/L vemurafenib (Vem); 20 hours]. B, Pearson correlation between inhibition of [3H]-2DOG uptake by vemurafenib and proliferation IC50s for vemurafenib treatment. l-lactate production (C) and ATP production (D) were determined in vemurafenib-treated melanoma cells (expressed as percentage change; control vs. 3 μmol/L vemurafenib; 20 hours). ECAR (E) and OCR (F) in human melanoma cells (percentage of control) determined using a Seahorse XF24 Extracellular Flux Analyzer. G, effect of vemurafenib on protein expression in melanoma cells was determined by Western immunoblotting (control vs. 3 μmol/L vemurafenib; 20 hours) using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control. H, membrane versus cytoplasmic GLUT1 and GLUT3 expression in melanoma cells (control vs. 3 μmol/L vemurafenib; 20 hours). Na+K+-ATPase was used as a membrane-specific loading control. I, gene expression of SLC2A1 (GLUT1), SLC2A3 (GLUT3), and HK2 (control vs. 3 μmol/L vemurafenib; 20 hours) was determined by quantitative real-time PCR (qRT-PCR). J, mRNA expression in melanoma biopsies. For all patients, RNA was extracted from fresh-frozen BRAFV600 melanoma biopsies obtained from patients pretreatment (Pre), early on dabrafenib (BRAFi) ± trametinib (MEK inhibitor), or vemurafenib treatment (BRAFi; EOT) and, in some cases, after disease progression (Prog). Data are included only for patients who showed stable disease or a partial response (RECIST criteria) EOT. Changes in gene expression were determined using an Illumina BeadStation (patients 1–7; ), Affymetrix Human Gene 1.0 ST Arrays (patient 8; ), or by RNAseq for patient 9 (). For all patients, data are expressed as the mean average signal intensity across all biopsies for an individual patient at each time point. K, change in SLC2A1 gene expression between baseline and EOT in responders [partial response (PR) or stable disease (SD)] versus nonresponders (progressive disease; PD) to BRAFi ± MEKi treatment. A, C and D, data represent mean ± SEM (n = 3). *, P < 0.05. Data were analyzed using a one-way ANOVA coupled with a Tukey multiple comparison post hoc test. E and F, data represent mean ± SEM (n = 5). *, P < 0.05. Data were analyzed using a one-way ANOVA coupled with a Tukey multiple comparison post hoc test. B, Pearson correlation, P < 0.001. I, data represent mean ± SEM (n = 3). *, P < 0.05. Two-way ANOVA coupled with a Tukey post hoc test. G and H, images are representative of two independent experiments. J, data points represent mean data values across all biopsies from a single patient pretreatment, and lines represent individual patients. Data were analyzed using t tests coupled with a Wilcoxon matched pairs signed-rank test and P < 0.05 denotes a statistically significant difference. K, lines represent mean fold-change in gene expression (EOT vs. Pre) and symbols represent individual patients. Data were analyzed using a t test coupled with a Mann–Whitney test, where P < 0.05 denotes a statistically significant difference. Tiffany J. Parmenter et al. Cancer Discovery 2014;4:423-433 ©2014 by American Association for Cancer Research